A polymer whose molecular backbone contains aliphatic esters. In other words, the parent nucleus R of the dihydroxyl compound HO -- R -- OH is polycarbonate of aliphatic group (CH2) M, (CH2)O(CH2), -- CH2 -- C(CH3)2 -- CH2 -- etc. It is characterized by low melting temperature, mostly below 60℃, and narrow melting range, greater solubility, low mechanical strength, hydrophilic, poor thermal stability, low glass transition temperature. Most aliphatic polycarbonate have low molecular weight and are mostly viscous liquid at room temperature or microcrystalline substance at low melting temperature. It can be prepared from aliphatic dihydroxyl compounds with dicarbonate or photogasification. Most of them have little industrial value, so their application is very limited. Aliphatic Polycarbonates Apc,Rigid Bioplastics Aliphatic Polycarbonates Apc,Adhesives Aliphatic Polycarbonates Apc,Binders Aliphatic Polycarbonates Apc Xingbang High Molecular Materials Co., Ltd. , https://www.chemicaladditive.com
Pharmaceutical excipients are the key to affecting the quality, even safety and efficacy of the formulation. China's pharmaceutical excipients are still relatively backward, first, the number is small, the second is China's non-accessory research institutions, and the third is the poor quality of excipients, which can be small. At the same time, the quality management regulations and policies for Chinese pharmaceutical excipients are numerous and difficult to implement.
From the perspective of the development strategy of the preparation industry, it is necessary to develop high-end innovative preparations with core competitiveness, adopt a variety of flexible cooperation methods, make full use of domestic and foreign resources and cost advantages, and identify new development directions and ideas. In combination with the development and frontiers of international pharmaceutical preparations, the following issues should be noted in the development of new formulations in China.
Emphasis on restructuring and development of the world's pharmaceutical companies have <br> <br> compression R & D funding, R & D institutions closed or cut R & D personnel, most companies focus on the development of new drug delivery systems (drugdeliverysystem, DDS) is. The market size of the new DDS in the United States in 2011 has reached 153.5 billion US dollars, compared with the previous 5 years, the average annual growth rate is nearly 16%. Therefore, it can be considered that DDS is obviously superior to the research and development of new physical drugs in terms of improving research and development speed, reducing development cycle, reducing R&D risk, and improving corporate profits. For example, five small nano-agents such as Hapamune developed by American company Elan using nanotechnology have been approved by the US FDA.
Encourage enterprises to go based <br> <br> in the process of going out, State Key Laboratory of companies can play a lead role. For example, many new preparations introduced by Shandong Green Leaf Company have been approved by the Chinese FDA and the US FDA for clinical research. In the context of the development of globalization, it is entirely possible that the company's independent intellectual property rights become international new drugs.
Study the application basis and industrial development of new formulations
There are still many shortcomings in the development of DDS in China. The problems of theory, technology, accessories, processes and equipment are the key issues that restrict their development. During the “Eleventh Five-Year Plan†and “Twelfth Five-Year Plan†period, the state increased its support and greatly mobilized the enthusiasm of R&D institutions and enterprises. In terms of nano pharmaceutical preparations, the US FDA has approved the listing of various types of nano-drugs, and small companies can also carry out innovative research and development through the formulation route. Although China is a big producer of "nano research papers", China has not yet approved a nano drug.
Strengthen research and development of pharmaceutical excipients and industrialization <br> <br> current domestic basic medicines are all generic drugs, of which more than 95% are common in tablets, capsules, etc., often have more than 100 or even more than 200 companies producing the same There are few companies that produce high-end products such as slow-release, controlled-release, and intelligent preparations, and there are not many companies that produce children's preparations. There are very few professional organizations engaged in research and development.
Drug release technology is the key to the development of high-end pharmaceutical preparations in China
Zyzhan guide: Drug release technology is the key to the development of high-end pharmaceutical preparations in China. From the perspective of industrial development strategy, preparations are high-tech industries, low-energy and low-pollution industries, high value-added industries, and production of APIs in China. The only way for big countries to develop into a strong pharmaceutical industry.